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New targeting agent in selective drug delivery 
nanocarriers for treating neuroblastoma.  
Gonzalo Villaverde,a Alejandro Baeza,a,* Gustavo J. Melen,b Arantzazu Alfranca,c 
Manuel Ramirezb and Maria Vallet-Regía,*  
Novel targeting agents based on meta-Iodobenzylguanidine (MIBG) moiety against neuroblastoma were 
synthetized and biologically evaluated for nanocarrier vectorization. These compounds have been 
anchored on the surface of drug loaded mesoporous silica nanocarriers causing improved cellular uptake 
in tumoral cells. Neuroblastoma (NB) is the most frequent extracranial pediatric tumor. Advanced forms 
of the disease (metastatic and/or refractory) have a dismal prognosis despite the combination of 
chemotherapy, radiotherapy, surgery and bone narrow transplant. These treatments carry severe side 
effects and, in some cases, compromise the patient life. MIBG has been widely applied in medical 
diagnosis of NB due to its affinity for the tumor cells through the norepinephrine transporter (NET), 
which is expressed in 90 % of NB. The exclusive accumulation of MIBG in neuroblastoma has been 
widely studied; however, its properties have been never exploited as targeting agent in nanocarrier drug 
delivery systems. Several structural analogues of MIBG have been prepared and attached on the 
nanocarrier surface. Their selective internalization has been tested against human neuroblastoma cells 
showing, in the best case, four times higher cellular uptake versus the naked nanosystem. Furthermore, 
in vivo experiments showed preferential and selective accumulation and retention of targeted 
nanosystem comparing with the naked and the just PEGylated counterpart systems. This novel 
nanosystem could be easily applicable for all kind of drug delivery nanocarriers, allowing a universal tool 
for neuroblastoma chemotherapies in the way to step down the classical approaches providing a 
newfangled nanosystem exclusively designed against this terrible malignancy. 
 
 
 
 
 
Introduction  
In recent years, the use of nanocarriers as selective drug 
transporters and theranostic proposes has attached much 
attention in nanomedicine applied to oncology. One of the 
biggest extra-benefits of using drug nanocarriers against cancer 
is that they can overcome some of the major limitations of 
conventional chemotherapy such as solubility issues associated 
with the frequently hydrophobic nature of cytotoxic drugs, 
short circulation lifetime and typical lack of selectivity.1 These 
problems are already addressed through the use of high doses in 
the treatment. This fact promotes the damage in healthy tissues 
causing the typical side effects associated to conventional 
chemotherapy. 
In order to improve the selectivity of the nanomedicines 
specific targeting agents have been designed along the years.2 
These targeted nanosystems are able to transport the cytotoxic 
compounds specifically to the target cells, and to release their 
payload once there. This fact causes the destruction of the 
malignant cells while minimizing the collateral damages in the 
surrounding tissue.3 For this reason, the development of new 
selective active targeting agents have become into one of the 
main challenges in nanomedicine.  
During last years, efficient ligand-receptor active targeting 
motifs such as RGD4,5,6 and folate,7,8,9,10 are commonly grafted 
on many different kinds of nanosystems surface for 
vectorization proposes. Furthermore, new specific moieties 
with multiple functionality using several types of cell-
penetrating peptides,11,12,13 or vasculature targeting  
antibodies,14,15,16 have been recently reported.  
The tumoral tissue accumulation characteristics of the 
nanoparticles is mainly possible due a specific passive targeting 
effect, which is based on the characteristic tumoral blood vessel 
architecture. These vessels present large pores and fenestrations 
of diameters up to few hundred nanometers. When the 
circulating nanoparticles reach a tumoral site, they pass through 
these pores being accumulated during longer times within the 
zone.17 Further, tumoral tissue also exhibits a poor lymphatic 
drainage. Both characteristics constitute the well-known 
enhanced permeation and retention effect (EPR) and is one of 
the main advantages constituting the basic of the goal standard 
of the use of nanoparticles in oncology.18 However, not all the 
cells which form a tumoral mass are malignant due the great 
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heterogeneity of these tissues that contain a large number of 
healthy supportive cells.19 The functionalization of the 
nanoparticle surface with molecules (targeting groups) able to 
be specifically recognized by the tumoral cells constitutes the 
so called active targeting. The presence of these groups is 
essential for enhancing the therapeutic efficacy of the 
nanomedicines.   
In this work, we are interested in developing effective 
nanocarriers that can be applied for neuroblastoma (NB) 
therapy. NB has being onto one of the challenging problems in 
pediatric oncology. This disease is the most frequent 
extracranial pediatric tumor which presents a dismal prognosis 
despite the combination of chemotherapy, radiotherapy, surgery 
and bone narrow transplant.20 Thus, the development of 
nanocarriers able to detect and destroy only the diseased cells 
may constitute a significant improvement in the treatment 
efficacy.21  
As mentioned above there is a wide range of studies which 
analyze the vectorization effect of generalist cancer targeting 
agents in nanoparticles. Bulky targeting agents such as, 
proteins, large peptides, aptamers, antibodies, etc., are 
commonly used. However, these agents have several possible 
binding interaction points, and are usually suitable to interact 
with unspecific proteins. Otherwise, small molecules with less 
binding spots may go unnoticed in this media. This fact could 
make the specific small moieties tolerable to body fluids 
maintaining its recognizing abilities only with the desired 
target. In special cases, some types of diseased cells have 
intrinsic and particular receptors that make it possible to 
improve the differentiation to each other. Thus, following this 
philosophy and looking for selective internalization in NB cells, 
meta-Iodobenzylguanidine (MIBG) looks the most suitable 
candidate for tuning the nanocarrier surface with vectorization 
proposes.22 MIBG targeting properties have been applied  in 
conventional medical diagnosis of NB in the last decades due to 
its affinity by the norepinephrine transporter (NET) which is 
expressed in 90 % of NB tumors.23   Because its high 
specificity for NB and other neuroendocrine tumors; MIBG 
effectiveness as tumor-targeted vehicle has been also applied in 
the therapeutic treatment by directed radiation using radioactive 
iodine (131I).24 Additionally, non-radioactive derivate has shown 
anticancer activity by itself.25 The conjugation of MIBG with 
antitumoral drugs not only enhances their selectivity against 
tumoral cells but also improves their cytotoxic capacity through 
synergic effect caused by tumor selective acidification by 
enhancement of glycolytic flux.26 This synergy may convert 
non-radioactive MIBG analogues into important targeting agent 
within the nanomedicine arena.  
MIBG-NET interaction may able to bring the nanosystem to 
NB cell internalization excluding healthy cells from the 
process. NET binding pocket is naturally designed for the 
recognition of small molecules which means that the size of the 
targeting motifs is limited. The binding mechanism is based on 
three main interactions: van der Walls interactions produced by 
several hydrophobic moieties from NET protein with the 
aromatic ring of the norepinephrine structure; several weak 
polar interactions through  hydrogen bonds, and, the key one; 
the ionic interaction between carboxylate group from Asp75 
from NET pocket and the protonated amine group from 
norepinephrine.27 Not by chance, MIBG is structurally close to 
norepinephrine, containing an aromatic core backbone 
responsible for the hydrophobic interactions and benzyl 
guanidine unit (pKa =12) able for proton capture which form a 
similar cationic specie than the norepinephrine amine group. 
(Figure 1). 
 
Figure 1. Structural equivalence between Norepinephrine, MIBG, MABG and 
MAmBG analogues. attachment on MSN and NET uptake. 
The possibility to perform structural modifications of MIBG in 
order to study and improve its uptake selectivity for 
norepinephrine transporter (NET), has been widely 
discussed.28,29,30 Several groups have been incorporated all sorts 
of variations in  para- position of the aromatic ring and even 
the aromatic ring have been replaced by a naphthyl or 
dibenzoazepine moiety without a significative loss of 
selectivity for the NET receptor.31 However, some authors 
suggest that the substitution of hydrogen in position 5 of the 
benzene ring is unfavourable for binding NET.32 On the other 
hand, the absence of the iodine atom in meta-position does not 
affect the uptake/selectivity properties. 
These previous structure-activity relationship studies (SAR) 
guided us to design, as a first approach, the synthesis of meta-
aminobenzyl guanidine (MABG) as MIBG analogue. MABG 
represents one of the simplest structurally accessible 
approximations to MIBG which keep the same aromatic ring 
and the guanidine recognition moiety in the same position. On 
the other hand, substitution of the iodine atom with amino 
group provides the grafting point to the nanoparticle surface 
through amide formation (Figure 1). 
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Scheme 1. Synthesis of MAmBG analogues.   
PPh3: Triphenylphosphine, DIAD: Diisopropyl azodicarboxylate, THF: Tetrahydrofuran DSS: Suberic acid bis(N-hydroxysuccinimide ester), Tol:Toluene, DCM: 
Dichloromethane, DIC: N,N'-methanediylidenebis(propan-2-amine), NHS: N-hydroxysuccinimide, NEt3: Triethylamine. 
The new analogue maintains the intrinsic properties from the 
original MIBG and makes the structure easy functionalizable 
for the further grafting step on MSN surface. 
Furthermore, the use of this amine/amide meta-substitution has 
been reported in tumor detection by Wang et al.33 with 
promising results in terms of selective accumulation in diseased 
tissues. However, this type of targeting agents have been never 
applied on nanocarriers for drug delivery. 
Results and discussion 
Herein, we report for the first time the use of novel MIBG 
analogues attached to mesoporous silica nanoparticles (MSN) 
used as nanocarrier model. These nanosystems are able to 
exclusively drive cytotoxic drugs to NB cells with minor 
impact for healthy supportive cells which are usually present in 
tumor mass. MSN have been widely used for nanomedicine 
proposes due to their excellent properties as easy 
functionalization, synthetic versatility, high loading drug 
capacity and economically low cost starting materials, among 
others.34,35,36,37 Furthermore, the external surface of these 
carriers can be easy decorated with targeting motifs which 
improve the selectivity and enhance the uptake rate in the 
malignant cells through receptor–ligand interactions.  
The attachment of MIBG based targeting compounds on MSN 
loaded with cytotoxic drugs could improve both the cytotoxic 
response and selectivity of the administered nanomedicines 
against NB cells.38,39,40  
In order to facilitate the monitorization of the cellular uptake 
process, MSNs were synthesized carrying fluorescein moieties 
covalently attached within the silica matrix following a 
variation of Stöber41 and van Blaaderen42 method. At the same 
time, amino groups were introduced on the external surface of 
the nanoparticles through this delayed co-condensation 
procedure yielding the naked material MSN-F-NH2.  
The XRD patterns for MSN-F-NH2 (See S.I., section B.1) 
shows three of the four low-angle reflections in the 2θ range 2-
8º typical of a hexagonal array as (100), (110), (200). These 
measurements suggest that the pore order was not affected by 
the introduction of fluorescein and the amino functionalization. 
A reduction of the peak intensity observed in (210) was not 
interpreted as a crystallinity lost but rather to a reduction in the 
X-ray scattering contrast in high functionalized material. 
Nitrogen absorption measurements showed a value for the total 
specific surface of 1192 m2/g and the adsorption/desorption 
isotherm is typical of non-filled mesoporous structure with a 
pore diameter of 2.5 nm. The size distribution profile of the 
nanoparticles was determined by dynamic light scattering 
(DLS) showing an average diameter of 190 nm which was 
confirmed by scanning electronic microscopy (SEM).
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Scheme 2. Targeting attachment on MSN. a) THF, corresponding analogue, 40ºC, overnight b) DCM, TFA, reflux, 72h. 
The presence of amino groups was confirmed by 
thermogravimetric analysis (around 8% in weight of organic 
material), FTIR and cross-polarization magic-angle spinning 
13C CP MAS solid state NMR. These amino groups will be 
employed as anchoring point of the targeting agents through 
amide formation reactions. Additionally, the free amino groups 
provided a positive charge (+40 mV) on the particle surface 
measured by zeta potential which enhanced the colloidal 
stability of these particles.  
MAmBG-type targeting agents were synthetized from a 
common starting material MABG-BOC (1), which was 
obtained from 3-aminobenzylalcohol and N,N-bis (tert-
butyloxycarbonyl) guanidine. The reaction follows a variation 
of  a Mitsunobu process previously reported  for guanidination 
of benzyl alcohols and affords the desired analogue with good 
yields.43,28 Then, MABG-BOC (1) was functionalized through 
amide group formation with the desired linkers which contain 
an activated acid group at the end of their chain yielding the 
MAmBG derivates (Scheme 1). 
This methodology provides a versatile pathway to explore the 
influence of the linker chain length in the cellular 
internalization. Two different categories of MAmBG analogues 
have been produced. One based on the use of short linkers 
between the grafting point and the targeting moiety 
(compounds 3 and 4, Scheme 1). And second, based on the use 
of longer linkers composed by polyethyleneglycol (PEG) 
chains of 2 and 10KDa of molecular weight, respectively 
(compounds 5 and 6, Scheme 1). Besides to separate the 
targeting agent far away from the surface which improves its 
interaction with the NET receptor, PEG linker may enhance the 
circulation time of the nanocarrier inside the blood stream 
through opsonisation abolition.44 This effect can be explained 
due steric interference from PEG chains that make the opsonins 
not able to be attached on the particle surface. Opsonization is 
the first step which allows that the nanoparticles will be 
recognized by the immune system leading to their clearance. 
System PEGylation increases the circulation time of 
nanoparticles that is essential for improving EPR effect 
efficacy. However, using longer PEG chains could affect the 
selectivity by shielding the targeting moiety reducing the 
possibilities of active uptake process.45 
The first MAmBG analogue, compound (3), was synthetized 
through two consecutive steps by treatment of MABG-BOC (1) 
with succinic anhydride affording isolated compound (2) in 
quantitative yield, following by transformation of the resulted 
acid in the corresponding activated succinimide ester (3). 
Compound (4) was obtained by direct reaction of MABG-BOC 
(1) with DSS in presence of NEt3. Long linked analogues were 
synthetized following the same methodology using 
commercially available PEG derivatives with double activated 
acid groups in both ends of the chain (for more synthetic 
information see S.I section A.1). The amounts of the MAmBG 
motif in each long linked compound were determined by UV 
spectrometry (See SI section A.2). The amount of 
benzylguanidine found in MAmBG-PEG2000-NHS (5) and 
MAmBG-PEG10000-NHS (6) was 7.7% w/w and 1.2% w/w, 
respectively. These data indicate that the reactions were 
resulted in around 50 % of yield in both cases, which was 
corroborated by 1H-NMR. The presence of the second activated 
acid group in the other side of the chain after condensation 
process was checked to ensure the posterior grafting process. 
(See S.I. section A.1). 
Deprotection of the BOC groups in all the synthetized 
analogues, makes the resulting compounds poorly soluble in 
most of solvents, except methanol or water. This fact,  convert 
their isolation in a tedious process. Additionally, it was 
necessary to employ forced conditions refluxing the media 
during 72h to obtain acceptable deprotection yields. Even then, 
unprotected MABG was isolated, however succinic derivate 
compound (2) lead its undesired meta-pyrrolidine derivate after 
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deprotection treatment through acid catalyzed cyclization. (See 
S.I, section A.1, MPyBG).  Therefore, we decided to anchor the 
BOC protected MAmBG analogues on the silica nanoparticles 
and once there, to carried out the BOC deprotection in order to 
make easier the BOC residues elimination and abolishing 
possible secondary products.  
Functionalization of nanoparticles always means a new 
challenge; one of the parameters more sticky in the synthesis of 
new hybrid material is to control the amount of organic material 
covalently immobilized on the surface. Parameters as stearic 
hindrance and charges, in both, nanoparticles surface and 
organic material, are key parameters for optimal 
immobilization. For this reason, optimization of the ratio of the 
MAmBG analogues in front of amine groups available for 
reaction in the surface is a must in each case. Acid activated 
MAmBG analogues were covalently grafted on MSN-F-NH2 by 
addition of the corresponding compound to a dispersion of 
nanoparticles in THF at 40ºC for 24 h, affording the materials 
MSN-(n)-BOC. Posterior BOC deprotection treatment with 
TFA/DCM yields the materials MSN-F-MAmBG with the 
MAmBG targeting moiety available to bind with NET (Scheme 
2). The amount of organic material covalently attached on the 
MSN surface was determined by TGA resulting in 
approximately 18.7 % (MSN-F-MAmBG-3-BOC), 11 % 
(MSN-F-MAmBG-4-BOC), 16.5 % (MSN-F-MAmBG-5-
BOC) and 20 % (MSN-F-MAmBG-6-BOC). The amount of 
targeting agents incorporated in each case was determined 
assuming a 1:1 equivalence in the case of the short linked 
analogues (3) and (4) and 7.7% w/w and 1.2% w/w for (5) and 
(6) respectively (previously calculated by UV spectrometry 
determination). In all cases, it should be considered that the 
blank material (MSN-F-NH2) has 8.2% w/w of organic 
material. Thus, the estimation of the targeting moiety 
functionalization in deprotected materials was 10.5 % and 3 % 
w/w for MSN-F-MAmBG-3 and MSN-F-MAmBG-4 
respectively, and 0.64 % and 0.14 % w/w for MSN-F-
MAmBG-5 and MSN-F-MAmBG-6 as maximum values. 
Obviously, the amount of MAmBG in PEGylated materials 
were lower than in the short linked. This fact may be attributed 
to both; the reaction conditions and the stearic hindrance of the 
PEG chains. However, less amount of targeting motif does not 
mean a minor selectivity, because the targeting agent may be 
more exposed in this case being more accessible for the 
interaction with the NET pocket.  
The presence of functional groups characteristic of MAmBG 
derivatives grafted on the nanoparticle surface was confirmed 
by cross-polarization magic-angle spinning 13C-NMR solid 
state. The spectra for each group of the shorter linked analogues 
were confronted with their counterparts in liquid state before 
immobilization, for both protected and unprotected materials as 
Figure 2 shows for MSN-F-MAmBG-3. 13C CP MAS solid 
state NMR spectra of short linked material MSN-F-MAmBG-3, 
both BOC protected and deprotected are totally recognizable in 
view of the corresponding derivatives before functionalization.  
 
Figure 2. Following the synthesis of MSN-F-MAmBG-3 by 
13
C CP MAS-NMR solid 
state spectra.  a) MSN-F-NH2 b) MAmBG (2) in chloroform c) MSN-F-MAmBG-3-
BOC d) MSN-F-MAmBG-3. 
The successful grafting process was confirmed by the 
apparition of the typical signals of MAmBG at approximately 
175 ppm (C=O) and 165 ppm (C=N), and undefined broad 
signals in down field corresponding with aromatic ring from 
benzylguanidine (Figure 2). 
On the other hand, the spectra in the case of long linked 
analogues  MSN-F-MAmBG-5-BOC and MSN-F-MAmBG-6-
BOC shows a dominant signal at 72 ppm (CH2) from PEG 
moiety which hide the rest of signals except the classical 
APTES signals which appears in all of them (See S.I, section 
B2 for more spectral data). Indeed, the PEG signal clearly 
indicates the presence of the PEG chains and, as consequence, 
the success of the functionalization process. Unfortunately, the 
tert-butyl signals from BOC protective group overlap with the 
APTES moiety and others aliphatic signals (CH2 from linker 
moieties) appearing as broad peaks. This fact makes impossible 
to determine the deprotection grade of the guanidine groups 
after the treatment with TFA by NMR. However, zeta potential 
measurements showed changes in the surface charge before and 
after the deprotection step, as show Table 1.  
In general, the surface charge becomes more positive after BOC 
deprotection which is in agreement with the presence of free 
guanidine groups.  Finally, the organic material determination 
by TGA reveals, in all cases, that the amount of organic 
material after functionalization is higher and it suffers a slight 
decrease after BOC deprotection. According with the DLS 
measurements, the functionalization process barely alters the 
nanoparticle size which is a very important aspect in drug 
delivery for antitumoral therapy (Table 1 and Figure 3a). The 
preservation of the particle size and the mesoporous structure of 
each material were confirmed by high resolution SEM  and 
TEM (Figure 3b and 3c) 
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Table 1. Characterization of MSN-F-MAmBG-n nanomaterials. 
N
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MSN-F-
NH2 
MSN-F-
MAmBG-
3-BOC 
MSN-F-
MAmBG-
3 
MSN-F-
MAmBG-
4-BOC 
MSN-F-
MAmBG-
4 
Z.Pot
(mV) 
+40 +36.6 +29.0 +24.1 +35.6 
Size 
(nm) 
190 176.5 190 214 231 
O.M 
% 
(w/w) 
8.2 15.5 11.3 18.7 18.2 
P
e
g
y
la
te
d
 m
a
te
r
ia
ls
  
MSN-F-
MAmBG-
5-BOC 
MSN-F-
MAmBG-
5 
MSN-F-
MAmBG-
6-BOC 
MSN-F-
MAmBG-
6 
 
Z.Pot
(mV) 
+19 +24.2 +12 +35.3  
Size 
(nm) 
208 237 214 226  
O.M 
% 
(w/w) 
16.4 12.5 20.22 15.5  
O.M :Organic Material. 
 
 
Figure 3. a) Size determination by DLS measurement. b) SEM micrographs of 
MSN-F-MAmBG-3 scale bars correspond to 100 nm. c) TEM micrographs of MSN-
F-MAmBG-5 scale bars correspond to 100 nm. 
Finally, XRD show that pore order was maintained after both 
functionalization and BOC deprotection processes in all 
materials. (See S.I sections B.2 and B.3). As mentioned above, 
there is a wide range of studies which analyze the vectorization 
effect of cancer targeting agents in nanoparticles. The 
nanosystems studied by in vitro assays, show selective avidity 
and internalization behaviour for tumor cells excluding the 
healthy ones. However, this effect is attenuated in replications 
of biological environment as multiproteic serum through the 
formation of protein corona in the nanoparticle surface.46,47 The 
interaction between the surface of the nanosystem and human 
body fluids is wholly influential in the targeting abilities of the 
nanosystems. The formation of protein corona in their surface 
changes the original physical-chemical properties of the entire 
system. This fact must be taken into account in order to perform 
a strict evaluation of the targeting effect of the grafted 
derivates. 
Usually, there are two differenced protein layers; the hard 
corona, formed by small size proteins, which is the closer and 
binder with the nanoparticle surface, and, the soft corona, 
formed by higher size proteins weakly bounded.48,49 The 
formation of the protein shell not only could diminish the 
internalization properties of the nanoparticles but also may 
hinder the targeting agent properties by protein unspecific 
interactions with undesired receptors. Thus, both; previous 
characterization of the nanosystem in serum multiproteic media 
and internalization assays in tumor environment emulation are 
essential. For this aim, the four targeted nanovehicles, as well 
as non-targeted nanomaterial MSN-F-NH2 were incubated in 
multiproteic serum Hyclone (36 g/L of estimated protein 
content) during 1.5 hours, centrifuged, washed and re-dispersed 
in water to be analyzed by DLS and z-potential. This assay 
allow to characterize the species could be formed in following 
internalization experiments which carried out in the serum 
media as emulation of real environment. 
Z-potential and size were analysed after the protein enriched 
serum exposition. Results presented in Table 2 shows how the 
presence of proteins in media clearly modifies the physico-
chemical properties of the surface in almost same magnitude 
due protein corona formation in all cases. 
In general, protein corona makes the nanosystems negatively 
charged and bulkier than its non-serum treated counterparts.  
 
Table 2. Characterization of MSN-F-MAmBG-n in serum media. 
 
 
 
MSN-
F-NH2 
MSN-F-
MAmBG-3 
MSN-F-
MAmBG-4 
MSN-F-
MAmBG-5 
MSN-F-
MAmBG-6 
 
Z
.-
P
ot
 
(m
V
) 
-23.4 -22.1 -22.5 -20.8 -21.9 
 
+40 +29.0 +35.6 +24.2 +35.3 
 
S
iz
e 
(n
m
) 
342 385 400 342 310 
 
190 190 231 237 226 
 
The data afforded equals the properties of all nanosystems, 
then, the possible differences of internalization to each other in 
neuroblastoma cells can be only explained by ligand-receptor 
interaction, MAmBG-NET in this case. 
In order to study the efficacy of the novel targeting agents to 
enhance the internalization capacity of the nanocarriers, human 
NB cells were incubated in the presence of each nanomaterial 
conjugated with the corresponding targeting agent at a fixed  
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Figure 4. a) Comparative internalization studies in NB cells between all nanosystems synthetized. b) Competitive assays for MSN-F-MAmBG-5 in NB cells with MIBG 
and MABG. c) Inhibition assays with ouabain for MSN-F-MAmBG-5 (100 μg/mL) in NB cells. 
concentration of 100 µg/mL during 2 hours in multiproteic 
serum culture.  After this time, the amounts of cells which had 
uptaked nanoparticles were determined by flow cytometry 
measuring the fluorescence at 488 nm as FITC+% representing 
the percentage of cells with fluorescence.  MSN-F-NH2 was 
chosen as the negative targeted control, not only by the fact of 
not being functionalized with targeting agent but also because 
is strongly positively charged (+40 mV) without serum 
treatment. The positively charged nanoparticles have shown the 
greatest efficiency in cell-membrane penetration and cellular 
internalization.50 Thus, the use of the MSN-F-NH2 as negative 
control; give a realistic idea of internalization capability of the 
targeted systems competing with a nanosystem with high 
internalization abilities.  
Results showed a notable internalization improvement in all 
targeted materials comparing with the non-targeted control 
MSN-F-NH2. Short linked derivates, MSN-F-MAmBG-3 and 
MSN-F-MAmBG-4 reflected differential behaviour regarding 
the internalization within NB cells.  
The succinic derivate MSN-F-MAmBG-3 internalization is 
notably higher than its longer linked colleague suberic acid 
derivate MSN-F-MAmBG-4. This behaviour is fully expected 
because the difference to each other in terms of percentage of 
targeting unit grafted in the surface (MSN-F-MAmBG-3, 
10.5% w/w versus MSN-F-MAmBG-4, 3% w/w).  
Similar effect has been found for long linker derivates, where 
the 2 KDa PEGylated derivate MSN-F-MAmBG-5 internalizes 
four times more than blank MSN-F-NH2 and possess 0.64 % 
w/w of targeting groups in contrast with 0.14 % w/w for 10 
KDa PEG derivate MSN-F-MAmBG-5 which internalizes 
almost two times more than the non-targeted material MSN-F-
NH2. 
Thus, comparing between derivates with proximally properties, 
the amount of effective targeting is a key parameter. This fact, 
clearly demonstrates the effect and the influence of targeting 
MAmBG moiety grafted in the nanoparticles surface for NB 
cells internalization proposes. In contrast, the comparison of the 
better derivates of both groups (succinic linked MSN-F-
MAmBG-3 from short linked group and 2 KDa PEG derivate 
MSN-F-MAmBG-5 from long linked analogues), reveals 
obvious alternative effects besides the targeting load effect. 
MSN-F-MAmBG-3 nanoparticles have showed less potential 
internalization comparing with 2 KDa PEGylated system MSN-
F-MAmBG-5. However the MSN-F-MAmBG-3 is grafted with 
more than twelve times of targeting agent. This behaviour could 
be connected with its more external configuration and 
disposition of the targeting moiety for interaction with NET 
pocket thanks to PEG linker, making the cellular uptake process 
more effective, even in presence of proteins in media. This fact 
improves the selective internalization for NB cells. The external 
disposition effect presented by 2 KDa PEGylated material, is 
hidden for 10KDa PEGylated material MSN-F-MAmBG-5. 
The increase in the length chain involves a dramatic fall of 
internalization caused by the possible shielding of the targeting 
moiety from the 10 KDa PEG combined with the low load of 
recognition moiety in this material surface. 
With the aim of confirming the ability of MAmBG derivates as 
targeting agents for nanosystems through ligand-receptor 
interaction, and, considering that, MIBG and norepinephrine 
are active in the specific uptake-1 mechanism which takes place 
through the active energy-consuming process by NET. 
Inhibition and competitive in vitro experiments for abolishing 
the active mechanism of the NET internalization were carried 
out for the derivate MSN-F-MAmBG-5. 
Uptake-1 can be inhibited by saturation of receptor and also 
through active mechanism blocker. Internalization for the MSN 
was measured with the presence of the commercially available 
MIBG (500 µM) and the derivate MABG (500 µM) in parallel 
assays. These analogues can saturate the cell receptors 
hampering the nanoparticle uptake directed by NET-grafted  
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 Figure 5. Confocal microscopy pictures. a) and b) Neuroblastoma cells 2h hours of incubation with 100μg/mL of MSN-F-MAmBG-5, blue DAPI for nuclei tracker, 
washed with glycine/NaCl buffer for eliminating non-internalized nanoparticles in the membrane cell surface. c) Neuroblastoma cells 2h hours of incubation with 
100μg/mL of MSN-F-MAmBG-5, blue DAPI for nuclei tracker, phalloidin as actin filaments marker and trypan blue for quenching non-internalized nanoparticles. d) 
Neuroblastoma cells 2h hours of incubation with 100μg/mL of MSN-F-NH2, blue DAPI for nuclei tracker, phalloidin as actin filaments marker and trypan blue for 
quenching non-internalized nanoparticles. 
MAmBG interactions. Internalization in NB cells data were 
confronted with afforded without any competitive NET 
receptor in the media. FITC+% measurements reflected a poor 
decrease of cells with internalized nanoparticles. However, the 
mean fluorescence indexes (MFI) data, representing intensity of  
fluorescence per cell, showed an interesting average of 34 % 
and 14 % of nanoparticles internalization decrease in the NB 
cells within MIBG and MABG presence respectively in MSN-
F-MAmBG-5 concentrations of 50 µg/mL and 100 µg/mL. 
Thus, the nanocarrier internalization is clearly trending down in 
excess of MIBG and MABG through saturation of NET. 
Furthermore, additional inhibition assays have been carried out 
abolishing the Na-K-ATPase dependent internalization process 
of MIBG through NET uptake-1. For this aim, ouabain (1 
mM)22,51 was added to NB cells culture as blocker of energy 
dependent mechanism before nanoparticles treatment.  
Internalization of targeted nanovehicles was reduced in 28 % 
compared to the internalization results without any blocker in 
media culture measured as mean fluorescence indexes. All 
these results suggest that the presence of MAmBG targeting 
agents in the nanosystems has an important influence in the 
selective internalization process through NET mediated up-
taking. This selective NET-MAmBG interaction is part of the 
total internalization mechanism of the whole system in NB 
cells. 
In order to confirm the internalization of MAmBG-nanoparticle 
systems in NB cells, confocal microscopy was applied. The 
internalization assay was carried out with the derivate MSN-F-
MAmBG-5, which exposed the best internalization properties 
in NB cells and naked nanosystem MSN-NH2 as control. 
(Figure 5) The accumulation of fluorescent nanoparticles MSN-
F-MAmBG-5 (Figure 5 a) b) and c)) in the NB cell cytosol is 
clearly evident in contrast with the negative control MSN-NH2 
(Figure 5 d)), confirming the higher selectivity and avidity of 
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Figure 6. In vivo homing of nanoparticles to neuroblastoma. a), Upper panels: images show fluorescence signal (F) of nanoparticles (P) 72h after i.v. 
injection. Lower panels: photograps show luminescent emission (L) of tumors (T) derived from s.c. injected NB-Luc. I: saline; II: MSN-Cy7-NH2; III: MSN-
Cy7-PEG; IV: MSN-Cy7-MAmBG-5. Note co-localization of both fluorescent (nanoparticles) and luminescent (tumor) specifically in MSN-Cy7-MAmBG-5 
(IV). Unspecific auto-fluorescence signal can be observed in all groups. b), Graphic shows mean + SD of fluorescence signal in each group 24, 48 and 
72h after injection of nanoparticles. II, III and IV as in A. Fluorescent signal in saline-injected mice was set as background in all cases. *p<0.5 and 
**p<0.1 vs. group IV. 
the targeted system. The capacity to deliver cytotoxic drugs to 
NB cells was evaluated as a proof of concept using the best 
material (MSN-F-MAmBG-5) and doxorubicin hydrochloride 
as drug model. Increased concentration of drug loaded 
nanoparticles were administered to NB and mesenchymal cells, 
selected as negative control due to their lack of NET receptor 
and their natural presence within the tumoral mass. The results 
show that more than 20% NB cells died at nanoparticle 
concentration of 50 µg/mL in only 2 hours whereas 
mechenchymal cells were barely affected (See SI, Figure S-45). 
Finally, in vivo experiments employing neuroblastoma murine 
models have been carried out in order to test the real 
effectiveness of the targeted nanocarrier which presented the 
best performance in the previous test. In order to monitor the 
tumor accumulation by IVIS imaging, the nanocarrier was 
labelled with Cy7 instead of fluorescein because this 
fluorescent probe is excited in the near infrared region whereas 
the biological tissues are transparent to this wavelength. This 
system corresponds to group IV (MSN-Cy7-MAmBG-5). A 
saline solution (Group I), naked nanoparticles (Group II, MSN-
Cy7-NH2) and PEGylated nanoparticles without targeting 
agents (Group III, MSN-Cy7-PEG) were used as controls. A 
xenograft murine model which presents stably expressing 
luciferase neuroblastoma tumors is used in order to allow an 
easy visualization of the tumoral mass by luminescence 
measurements. 
The results clearly show that the nanoparticles functionalized 
with the complete targeting system (group IV) present a 
significative accumulation within the tumoral mass at 48 and 72 
hours after the administration, which is clearly visible by the 
strong fluorescent signal located in the tumoral region.  In 
contrast, the naked and PEGylated particles (groups II and III, 
respectively) barely exhibited fluorescence in this zone (Figure 
6a). It is important to remark that the nanoparticles 
functionalized with the MABG analogue remain in the tumoral 
tissue after 72 hours whereas the naked and PEGylated ones are 
rapidly cleared from the zone (Figure 6b). These findings 
confirm the efficacy of this targeting agent due to improve not 
only the selectivity of the nanocarriers but also enhance their 
retention within the diseased tissue. 
Experimental 
Materials and Methods 
Following compounds were purchased from Sigma-Aldrich 
Inc.:N,N'-methanediylidenebis(propan-2-amine) (DIC), N-
hydroxysuccinimide (NHS), N,N-bis(tert-butyloxycarbonyl) 
guanidine, (3-aminophenyl)methanol, Triphenylphosphine 
(TPP), Diisopropyl azodicarboxylate (DIAD), Suberic acid 
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bis(N-hydroxysuccinimide ester (DSS), O,O′-Bis[2-(N-
Succinimidyl-succinylamino)ethyl]polyethylene glycol 2KDa 
and 10KDa, doxorubicin hydrochloride (European 
Pharmacopoeia), m-Iodobenzylguanidine hemisulfate salt,  
aminopropyltriethoxysilane (APTES), ammonium nitrate, 
cetyltrimethylammonium bromide (CTAB), tetraethyl 
orthosilicate (TEOS).  All other chemicals (absolute ethanol, 
acetone, ethyl acetate heptane, dry solvents etc.) were of the 
best quality commercially available and they have been 
employed as received. 
Characterization techniques. 
Powder X-ray diffraction (XRD) experiments were performed 
with a Philips X’Pert diffractometer equipped with Cu Kα 
radiation (wavelength 1.5406 Å). XRD patterns were collected 
in the 2θ range between 0.6º and 8 with a step size of 0.02º and 
counting time of 5 s per step. Fourier transform infrared 
spectroscopy (FTIR) in a Thermo Nicolet nexus equipped with 
a Goldengate attenuated total reflectance device. The textural 
properties of the materials were determined by nitrogen 
sorption porosimetry by using a Micromeritics ASAP 2010. To 
perform the N2 measurements, the samples were previously 
degassed under vacuum for 24 h at room temperature. 
Thermogravimetry analysis (TGA) were performed in a Perkin 
Elmer Pyris Diamond TG/DTA analyzer, with 5 ºC/min heating 
ramps, from room temperature to 600 ºC. The hydrodynamic 
size of mesoporous nanoparticles was measured by means of a 
Zetasizer Nano ZS (Malvern Instruments) equipped with a 633 
nm “red” laser. Mass spectra were acquired with a Voyager 
DE-STR Biospectrometry MALDI-TOF mass spectrometer. 
Scanning electron microscopy (SEM) analyses were made on a 
JEOL 6400-LINK AN10000 microscope (Electron Microscopy 
Centre, UCM). The samples underwent Au metallization 
previous to observation. Liquid NMR experiments were made 
in a Bruker AV 250MHz. Solid phase NMR MAS experiments 
were carried out in a Avance 400MHz. GPC analysis were 
made in a Waters 2695 with Refractive Index Detector Waters 
2414. 
Calculation procedures. 
The surface area was determined using the Brunauer-Emmett-
Teller (BET) method and the pore volume, Vpore (cm
3·g-1), was 
estimated from the amount of N2 adsorbed at a relative pressure 
around 0.99. The pore size distribution between 0.5 and 40 nm 
was calculated from the desorption branch of the isotherm by 
means of the Barrett-Joyner-Halenda (BJH) method. The 
mesopore size, Øpore (nm), was determined from the maximum 
of the pore size distribution curve. 
Synthesis of starting amino functionalized nanoparticles MSN-F-
NH2 
FITC (1mg) and APTES (2,2 µL) were solved in the minimum 
volume of EtOH, the mixture was stirred at room temperature 
for 2 hours under inert atmosphere. The resulting mixture 
(Solution1) was added under a mixture of TEOS (4.5 mL) and 
APTES (0.5 mL) also in inert conditions. The resulting mixture 
(Solution 2) was added dropwise with gentle stirring under a 
solution formed by 1g of CTAB, 480 mL of water and 3.5 mL 
of NaOH 2M at 80 ºC . The final reaction mixture was stirred at 
80ºC during 2 hours. Yellow solid was filtered and washed with 
water and EtOH. 
For template removing, solid was suspended in a solution of 
NH4NO3 (10 mg/mL) of EtOH/H2O in reflux during 48h. 
The solid was filtered, washed EtOH and dried in reduce 
pressure oven at 40ºC during 24h. 1.2 g of product was 
afforded. The solid was functionalized with 6.22x10-4 mol/gr of 
amine groups.52 
Synthesis of functionalized nanoparticles MSN-F-MAmBG-n 
Compounds (3), (4), (5) and (6) were previously synthetized 
following Scheme 1. and fully characterized. (See S.I. Section 
A.1) 
For the synthesis of MSN-F-MAmBG-n 100 mg of solid 
starting material MSN-F-NH2 (6.22x10
-4mol/gr primary amines 
ready to react) were dried under reduce pressure at 80ºC placed 
in a Schlenk during 3 hours. The solid was lead to room 
temperature and suspended in 20 mL of dried THF, still under 
inert atmosphere, the dispersion was sonicated during 10 
minutes. A solution of 35mg (3), 38 mg (4) (Ratio 
NH2(solid)/acid activated derivate 1:1), 25 mg (5) (Ratio 
NH2(solid)/acid activated derivate 1: 0.20), 64 mg (6) (Ratio 
NH2(solid)/acid activated derivate 1: 0.10) respectively in THF 
(3 mL) was added dropwise with gentle stirring. The ratios of 
functionalization process were chosen in order to abolish 
saturation of the nanoparticles surface in each case. When the 
addition was finalized the resulted dispersion was warmed to 40 
ºC overnight. 
The resulted yellow solid was washed with THF (3x15mL) and 
EtOH (3x15) and characterized.  
General proceed for nanomaterial guanidine deprotection 
MSN-F-MAmBG-3-BOC, MSN-F-MAmBG-4-BOC, MSN-F-
MAmBG-5-BOC, MSN-F-MAmBG-6-BOC (100 mg in each 
case) were dried under reduce pressure at 80ºC placed in a 
Schlenk during 3 hours. The solids were lead at room 
temperature and 10 mL of deprotection cocktail (TFA/DCM 
1:1) was added dropwise under inert atmosphere. The mixture 
was sonicated during 10 minutes and raised to 65ºC with gentle 
stirring 72 hours. 
Solid were filtered and washed with DCM, brine and EtOH. 
Finally, the new materials were dried under vacuum at 40 ºC 
and characterized. 
Internalization assay 
Neuroblastoma cell line NB1691-luc was seeded in 24-well 
plates at 5000 cells/cm2. Cells were exposed to 100 µg/ml of 
MSN-F-NH2, MSN-F-MAmBG-3, MSN-F-MAmBG-4, MSN-
F-MAmBG-5 or MSN-F-MAmBG-6 for 2 hours at 37ºC, 5% 
CO2 and 95% humidity. Cells were then washed and harvested. 
The number of FITC+ cells was evaluated by flow cytometry 
using the FACSCanto II flow cytometer and the FACSDiva 
software v6.1.2 (BD Biosciences, San Jose, Ca.). Percentages 
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of FITC+ populations are shown as the mean of two 
independent replicates. 
 
 
Competition and Inhibition assays 
Following the same set up as for the internalization assay 50 
µg/ml and 100 µg/ml MSN-F-MAmBG-5 uptake was 
challenged in the presence of 500 µM MIBG or derivative 
MABG. Cells were pre-incubated during 15 min with either 
competitor. After a medium changed containing both MSN-F-
AmBG-5 and MIBG or MABG the incubation proceeded for 2 
more hours. The inhibition assay with 1mM ouabain was 
performed as published elsewhere.22 In both cases, the number 
of FITC+ cells was evaluated by flow cytometry as in the 
previous experiment. Mean fluorescence indexes and 
percentage of FITC+ populations are shown as the mean of two 
independent replicates. 
Confocal Imaging 
For confocal analysis cells were seeded on glass chamber slides 
(LabTek II, Nunc, Rochester, NY) and incubated with 100 
µg/ml MSN-F-AmBG-5 or MSN-F-NH2 for 2 hours. 
Internalization was stopped by washing cells with ice-cold PBS 
followed by two acid washes with 250mM NaCl, 100mM 
glycine pH 2.5 to remove any adsorbed particles. Cells were 
then fixed in 4% PFA, stained with Texas Red-X phalloidin 
(Molecular Probes, Eugene, OR) and mounted in DAPI-
containing Fluoroshield (Sigma, St. Louis, MO). Images were 
capture via a 63×/1.4 oil-immersion objective on the Leica SP5 
confocal microscope and the Leica LAS AF software. 
In vivo homing/biodistribution assays. 
Human neuroblastoma NB-1691 cells (kindly provided by Dr. 
Antonio Pérez, Hospital La Paz, Madrid) were transduced with 
pHRSIN-CS-Luc-IRES-emGFP-WdlNotI lentiviral vector 
(kindly provided by Dr. Antonio Rodríguez, Universidad 
Autónoma de Madrid) in order to generate a stably expressing 
luciferase neuroblastoma cell line (NB-Luc). 2.5x106 NB-Luc 
cells were subcutaneously injected into the left flank of 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG; Jackson) 
immunodeficient mice. Three weeks later, 200µl of saline 
(group I) or 1mg of either Cy7-labeled bare nanoparticles 
(group II), PEG-covered nanoparticles (group III) or MIBG-
PEG-covered nanoparticles (group IV), were inoculated i.v. 
into these mice. In vivo biodistribution of Cy7-labeled 
nanoparticles was monitored through fluorescent image 
acquisition in an IVIS Lumina XRMS (Perkin Elmer) at 24, 48 
and 72h after nanoparticles injection. The presence and 
localization of NB-Luc-derived tumors was confirmed through 
the detection of luminescent signal after i.p. injection of 
1.25mg/mice D-Luciferin (Perkin Elmer). Image analysis was 
performed with Living Image® 4.4 software (Perkin Elmer). 
Animal studies were in accordance with the guidelines of the 
EU on animal care (2010/63/EU) and approved by the 
institutional ethics committee (Comité de Ética de la 
Investigación y Bienestar Animal ISCIII; procedure CBA PA 
25_2011-v2). 
 
Conclusions 
In conclusion, different novel targeting agents based on MIBG 
structure have been synthesized and grafted on the surface of 
mesoporous silica nanoparticles, employed as carrier model. 
This type of structure has been chosen due to the well-known 
affinity of MIBG for the norepinephrine transporter which is 
highly expressed by neuroblastoma cells. The efficacy of each 
targeting agent to induce an enhanced nanocarrier cellular 
uptake have been tested using neuroblastoma cell line NB1691-
luc, showing in the best case an increase of up to four times. 
This system was able to work in a serum multi-proteic media, 
keeping the targeting properties of the grafted agent coexisting 
with protein corona effect. Furthermore, drug loaded targeted 
nanoparticles showed high exclusive cytotoxic effect in NB 
cells. Finally, the in vivo efficacy of these carriers was tested 
using murine neuroblastoma models. The results indicate that 
the surface functionalization with these targeting agents 
provokes a significative higher tumoral tissue accumulation and 
retention in comparison with the non-decorated particles.  This 
type of selective targeting agents could be easily applied to 
different nanoparticle platforms paving the way for the 
application of novel nanomedicines for the treatment of 
neuroblastoma.  
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